Impact of Anti-cytomegalovirus Treatment in the Management of Relapsing Ulcerative Colitis Requiring Vedolizumab Therapy
Megadott ok: low of inclusions
Key facts
- Where
- Annecy, Clermont-Ferrand, Lyon, Montpellier, Nice, Paris, Rouen és Saint-Etienne, FranciaországSee the 8 sites
- Phase
- 3. fázis
Where in Franciaország
- CH d'ANNECYAnnecy, FranciaországNo longer taking part
- CHU de Clermont-FerrandClermont-Ferrand, FranciaországNo longer taking part
- CHU de Lyon SudLyon, FranciaországNo longer taking part
- CHU de MontpellierMontpellier, FranciaországNo longer taking part
- CHU de NiceNice, FranciaországNo longer taking part
- APHP - Hôpital Saint AntoineParis, FranciaországNo longer taking part
- CHU ROUEN - Service Gastro-entérologieRouen, FranciaországNo longer taking part
- Chu de Saint EtienneSaint-Etienne, FranciaországNo longer taking part
Trial details
- Who runs it
- Centre Hospitalier Universitaire de Saint Etienne
- Trial code
- NCT04064697
- Record updated
- 2024. április 10.
- Original description
Ulcerative Colitis (UC) is an inflammatory bowel disease that can require the use of anti-TNF alpha therapy. When anti-TNF alpha failed to obtain a clinical response, the use of a new anti-integrin therapy, vedolizumab, can be proposed. The efficacy of vedolizumab has been assessed in a phase 3 study (GEMINI I), with response rates of 41.1% with vedolizumab vs 25.5% with placebo.Read full original descriptionShow less
Impact of Anti-cytomegalovirus (Valganciclovir) Treatment in the Management of Relapsing Ulcerative Colitis (UC) Requiring Vedolizumab Therapy: a Randomized Clinical Trial Comparing a Strategy With or Without Antiviral Therapy.
Ulcerative Colitis (UC) is an inflammatory bowel disease that can require the use of anti-TNF alpha therapy. When anti-TNF alpha failed to obtain a clinical response, the use of a new anti-integrin therapy, vedolizumab, can be proposed. The efficacy of vedolizumab has been assessed in a phase 3 study (GEMINI I), with response rates of 41.1% with vedolizumab vs 25.5% with placebo.
CytoMegaloVirus (CMV) reactivation has been associated with resistance to steroid and to several lines of immunosuppressive therapy. Antiviral therapy was proven to decrease the tissue viral load and to restore the response to immunosuppressive therapies (up to 80% in small group of patients). A recent meta-analysis supports the use of valganciclovir in case of CytoMegaloVirus (CMV) reactivation in active Ulcerative Colitis (UC).
Moreover, a study showed that the risk of CMV reactivation seems to be more important with vedolizumab than with anti TNF, and the risk of colectomy is higher in case of CytoMegaloVirus (CMV) reactivation (p<0.05).
Inclusion: Patient with moderate to severe active Ulcerative Colitis (UC) defined by a Mayo score greater than 5; Patient with an inflammatory outbreak of Ulcerative Colitis (UC) :; without anti-TNF; under anti-TNF (infliximab, adalimumab, golimumab) after induction (no primary response) or clinical recurrence (secondary failure); Having rectosigmoidoscopy with an endoscopic Mayo score≥ 2 with 2 biopsies of the inflammatory tissue; Presence of a CytoMegaloVirus (CMV) infection in the inflammatory tissue (viral load greater than 5 IU / 100000 cells by qPCR); Patient with a negative pre-treatment assessment including HIV, HBV, HCV, HCV serology, a negative quantiferon or a history of tuberculosis preventive treatment adapted by Rifinah or Rimifon; Signed informed consent.
Exclusion: Patient with intolerance or contraindications to current therapy; Patient who received a live vaccine in the month preceding the study; Patient with Human Immunodeficiency Virus (HIV)+, hepatitis B, hepatitis C, tuberculosis; Clostridium difficile infection; Patients with severe renal insufficiency defined by creatinine clearance <30ml/minute, or hemodialysed; Patient with severe acute colitis; Patient treated by ciclosporin or Prograf; Pregnant or starts breastfeeding.